Prenatal Intraportal Delivery of Polymeric Nanoparticles to Fetal Rhesus Monkeys ( Macaca mulatta )
Year: 2026
Type: article
Abstract: Preliminary investigations focused on biodistribution of polymeric nanoparticles (NPs) shortly after ultrasound-guided delivery via the portal vein in early second-trimester fetal rhesus monkeys. Results demonstrated that poly(lactic-co-glycolic acid) (PLGA) NPs ( N = 3; 3 mg administered at 75–80 days gestational age) and poly(amine-co-ester)-polyethylene glycol (PACE-PEG) NPs ( N = 3; 3 mg at 75–80 days gestational age) distributed to fetal tissues when assessed 24 h post-administration. No adverse findings were observed. PLGA NPs were found primarily in the fetal liver and spleen, whereas PACE-PEG NPs showed more widespread biodistribution to a range of anatomical sites. In another fetal subset with PACE-PEG NPs ( N = 2; 90 days gestational age) assessed within 48-h post-administration, results demonstrated enhanced green fluorescent protein reporter mRNA expression in select tissues. These early-stage short-term studies suggest that polymeric NPs, particularly those composed of PACE-PEG, can be safely administered and are potential candidates for fetal delivery of therapeutic nucleic acids. While preliminary, these studies provide evidence to support further investigations in this species to address long-term safety and efficiency.
Source: Human Gene Therapy
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: Ultrasound Imaging for Nonhuman Primate Translational Research, Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung, G4998615386, Nonhuman Primate IVIS Spectrum Imaging System, Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools, Optimization of Polymeric Nanoparticles Encapsulating Peptide Nucleic Acids for In Utero Gene Editing of the Fetal Brain., Targeted correction of the human CFTR gene, PNA Nanoparticles for Gene Editing In Vivo, G738160294, G9000004645, G9000250825, Medical Scientist Training Program, G9000324189, Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis
OpenAlex ID: W7127974764
